Ascendis Pharma A/S $ASND Shares Purchased by Creative Planning

Creative Planning raised its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 48.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,383 shares of the biotechnology company’s stock after purchasing an additional 1,746 shares during the period. Creative Planning’s holdings in Ascendis Pharma A/S were worth $929,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. Compagnie Lombard Odier SCmA purchased a new stake in Ascendis Pharma A/S in the 2nd quarter valued at approximately $39,000. First Horizon Advisors Inc. acquired a new position in Ascendis Pharma A/S in the 2nd quarter valued at $41,000. Brooklyn Investment Group grew its holdings in Ascendis Pharma A/S by 332.9% in the 1st quarter. Brooklyn Investment Group now owns 355 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 273 shares during the period. Hantz Financial Services Inc. boosted its holdings in Ascendis Pharma A/S by 291.1% in the second quarter. Hantz Financial Services Inc. now owns 352 shares of the biotechnology company’s stock valued at $61,000 after acquiring an additional 262 shares during the last quarter. Finally, LVW Advisors LLC acquired a new stake in Ascendis Pharma A/S during the second quarter worth about $202,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on ASND shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Ascendis Pharma A/S in a research note on Wednesday, October 8th. Stifel Nicolaus boosted their price objective on Ascendis Pharma A/S from $212.00 to $254.00 and gave the stock a “buy” rating in a research note on Friday, August 8th. Bank of America increased their target price on Ascendis Pharma A/S from $227.00 to $230.00 and gave the company a “buy” rating in a research note on Tuesday, September 2nd. Raymond James Financial started coverage on Ascendis Pharma A/S in a report on Friday, October 17th. They set a “strong-buy” rating and a $271.00 target price on the stock. Finally, UBS Group restated a “buy” rating and issued a $307.00 price target (up previously from $306.00) on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $256.60.

Ascendis Pharma A/S Stock Performance

Shares of ASND opened at $212.44 on Monday. The company has a 50-day simple moving average of $204.38 and a 200-day simple moving average of $188.30. Ascendis Pharma A/S has a 52 week low of $118.03 and a 52 week high of $223.18. The firm has a market capitalization of $13.11 billion, a P/E ratio of -41.17 and a beta of 0.44.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Wednesday, November 12th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.76). The company had revenue of $290.24 million during the quarter, compared to analysts’ expectations of $246.91 million. As a group, equities analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.